Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| ImaRx Therapeutics, Inc. (NASDAQ: IMRX) | Delayed: 3.81 +0.07 (1.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.74 | 52 Week High | $0.04 | |||
| Open | $3.72 | 52 Week Low | $0.00 | |||
| Day High | $3.84 | P/E | N/A | |||
| Day Low | $3.70 | EPS | $-0.09 | |||
| Volume | 527,135 | |||||
